Psychopharmacology and Psychiatry Updates INTEGRATE Guidelines: Standardizing Schizophrenia Pharmacotherapy
Jan 11, 2026
Dr. Oliver Freudenreich, a leading psychiatrist in psychopharmacology, shares insights from the newly released INTEGRATE guidelines for schizophrenia treatment. He discusses the importance of establishing a universal treatment algorithm to enhance care standards. Key points include the early use of long-acting injectables and clozapine for treatment-resistant patients, as well as recommendations for first-episode antipsychotics. Freudenreich emphasizes shared decision-making and integrating medical management for optimal patient outcomes.
AI Snips
Chapters
Transcript
Episode notes
Global Standard For Schizophrenia Care
- The INTEGRATE guidelines create a universal, algorithmic roadmap for schizophrenia pharmacotherapy.
- They aim to reduce harmful international variability while preserving patient-centered flexibility.
Variable Clozapine Use Reflects Care Gaps
- Variability in clozapine use across countries signals inconsistent care rather than justified differences.
- A universal guideline helps ensure clozapine is used appropriately wherever patients live.
Initial Drug Choice And Early LAI Consideration
- Start first-episode patients on aripiprazole 5 mg if there is no strong preference, and titrate as needed.
- Offer long-acting injectables early after establishing tolerability, not only for poor adherence.